Wuxi Biologics, a Chinese company that makes ingredients for AstraZeneca’s COVID-19 vaccine, may be a step closer to being taken off a US trade list that it landed on five months ago, wiping HK$77 billion ($9.9 billion) off its market value.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
